In today’s session Regeneron Pharmaceuticals Inc (REGN) recorded an unusually high (292) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the January, 2017 put, expecting serious REGN decrease. With 292 contracts traded and 4574 open interest for the Jan, 17 contract, it seems this is a quite bearish bet. The option with symbol: REGN170120P00350000 closed last at: $12.4 or 8.8% up. The stock decreased 1.40% or $5.62 during the last trading session, hitting $397.2. About 557,513 shares traded hands. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has declined 1.80% since March 1, 2016 and is downtrending. It has underperformed by 11.04% the S&P500.
Analysts await Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to report earnings on November, 2. They expect $2.27 earnings per share, down 12.36% or $0.32 from last year’s $2.59 per share. REGN’s profit will be $239.52M for 43.74 P/E if the $2.27 EPS becomes a reality. After $2.11 actual earnings per share reported by Regeneron Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 7.58% EPS growth.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Ratings Coverage
Out of 19 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 9 rate it a “Buy”, 1 “Sell”, while 9 “Hold”. This means 47% are positive. $700 is the highest target while $325 is the lowest. The $564.23 average target is 42.05% above today’s ($397.2) stock price. Regeneron Pharmaceuticals Inc. has been the topic of 40 analyst reports since July 28, 2015 according to StockzIntelligence Inc. Credit Suisse initiated the stock with “Neutral” rating in Wednesday, January 20 report. The rating was maintained by Bernstein on Wednesday, August 5 with “Outperform”. On Wednesday, June 29 the stock rating was initiated by Bernstein with “Outperform”. UBS maintained it with “Sell” rating and $565 target price in Wednesday, August 5 report. The firm earned “Market Perform” rating on Wednesday, April 20 by Wells Fargo. On Wednesday, August 5 the stock rating was maintained by RBC Capital Markets with “Outperform”. The rating was maintained by RBC Capital Markets with “Outperform” on Monday, July 27. Leerink Swann initiated the shares of REGN in a report on Friday, February 5 with “Outperform” rating. The stock has “Outperform” rating given by Leerink Swann on Monday, August 3. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned “Neutral” rating by TH Capital on Monday, August 10.
Insitutional Activity: The institutional sentiment increased to 1.19 in Q2 2016. Its up 0.44, from 0.75 in 2016Q1. The ratio improved, as 51 funds sold all Regeneron Pharmaceuticals Inc shares owned while 154 reduced positions. 50 funds bought stakes while 193 increased positions. They now own 70.88 million shares or 9.49% less from 78.30 million shares in 2016Q1.
Hudock Grp Lc last reported 0.03% of its portfolio in the stock. Gsa Cap Prtn Limited Liability Partnership has 0.31% invested in the company for 16,039 shares. D Scott Neal Inc holds 0.01% or 47 shares in its portfolio. Alpha Windward Ltd Liability has 0.07% invested in the company for 292 shares. Cambridge Advsr has 2,747 shares for 0.02% of their US portfolio. Prentiss Smith And has 0.03% invested in the company for 175 shares. Pacad Investment Ltd holds 0.3% of its portfolio in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 6,200 shares. Macquarie holds 0.02% or 35,214 shares in its portfolio. Bank Of Montreal Can accumulated 36,213 shares or 0.01% of the stock. Tci Wealth Advisors Inc has 3 shares for 0% of their US portfolio. Moreover, Joel Isaacson & Ltd Limited Liability Company has 0.22% invested in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 3,000 shares. Winfield Assocs has 15 shares for 0% of their US portfolio. Clinton Grp Inc last reported 2,766 shares in the company. Moreover, Fmr Ltd Liability Corp has 0.45% invested in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 9.42M shares. Da Davidson And holds 64 shares or 0% of its portfolio.
Insider Transactions: Since April 6, 2016, the stock had 1 insider buy, and 3 insider sales for $20.55 million net activity. Another trade for 2,000 shares valued at $850,000 was sold by GOLDSTEIN JOSEPH L. Sanofi bought $23.55 million worth of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on Tuesday, June 14. Shares for $396,640 were sold by RYAN ARTHUR F on Tuesday, May 24. The insider Van Plew Daniel P sold 4,413 shares worth $1.70M.
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical firm that discovers, invents, develops, makes and commercializes medicines for the treatment of serious medical conditions. The company has a market cap of $41.91 billion. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. It has a 62 P/E ratio. It commercializes medicines for eye diseases, high low-density lipoprotein cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of unmet medical need, including oncology, rheumatoid arthritis (RA), asthma, atopic dermatitis, pain and infectious diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.